Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Comparative, Multicenter, Phase 2 Clinical Study to Evaluate Efficacy and Safety of Two Doses of LND101001 Monotherapy in Patients with Mild to Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs LND 101001 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Lupin
- 27 Jul 2020 Status changed from recruiting to completed.
- 14 Dec 2016 This trial has been completed in Croatia (end date: 29 Aug 2016).
- 30 Nov 2016 This trial has been completed in Poland (End date:2016-08-29) as per European Clinical Trials Database record.